Vardenafil hydrochloride Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
Vardenafil hydrochloride Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
Vardenafil hydrochloride Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
Vardenafil hydrochloride Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
Vardenafil hydrochloride Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
Varenicline (CP 526555) is a selective α4β2 nicotinic receptor partial agonist, it stimulates nicotine receptors more weakly than nicotine itself does.
Varenicline (CP 526555) is a selective α4β2 nicotinic receptor partial agonist, it stimulates nicotine receptors more weakly than nicotine itself does.
Varenicline (CP 526555) is a selective α4β2 nicotinic receptor partial agonist, it stimulates nicotine receptors more weakly than nicotine itself does.
Varenicline (CP 526555, Chantix, Champix) dihydrochloride is a potent, partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR) and α3β4 nAChR with EC50 of 2.3 μM and 55 μM, respectively. Varenicline dihydrochloride is a potent, full agonist of α7 nAChRs with EC50 of 18 μM. Varenicline is a prescription medication used for smoking cessation.
Varenicline (CP 526555, Chantix, Champix) dihydrochloride is a potent, partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR) and α3β4 nAChR with EC50 of 2.3 μM and 55 μM, respectively. Varenicline dihydrochloride is a potent, full agonist of α7 nAChRs with EC50 of 18 μM. Varenicline is a prescription medication used for smoking cessation.
Varenicline (CP 526555, Chantix, Champix) dihydrochloride is a potent, partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR) and α3β4 nAChR with EC50 of 2.3 μM and 55 μM, respectively. Varenicline dihydrochloride is a potent, full agonist of α7 nAChRs with EC50 of 18 μM. Varenicline is a prescription medication used for smoking cessation.
Varenicline hydrochloride is a potent partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR) and α3β4 nAChR, with EC50s of 2.3 μM and 55 μM, respectively. In addition, Varenicline hydrochloride is also a potent full agonist of α7 nAChRs. In addition, Varenicline hydrochloride is a potent full α7 nAChRs agonist with an EC50 of 18 μM.